Dainippon Sumitomo makes good on US oncology marketing plans
This article was originally published in Scrip
In a new mid-term business plan released earlier this year, Dainippon Sumitomo Pharma (DSP) said it was aiming to build up its independent US sales and marketing capability in the oncology field, using the 2012 acquisition of Boston Biomedical as a foundation.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.